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Abstract
Mitochondrial DNA (mtDNA) variation has recently been suggested to have an association with various cancers, including
prostate cancer risk, in human populations. Since mtDNA is haploid and lacks recombination, specific mutations in the
mtDNA genome associated with human diseases arise and remain in particular genetic backgrounds referred to as
haplogroups. To assess the possible contribution of mtDNA haplogroup-specific mutations to the occurrence of prostate
cancer, we have therefore performed a population-based study of a prostate cancer cases and corresponding controls from
the Korean population. No statistically significant difference in the distribution of mtDNA haplogroup frequencies was
observed between the case and control groups of Koreans. Thus, our data imply that specific mtDNA mutations/lineages
did not appear to have a significant effect on a predisposition to prostate cancer in the Korean population, although larger
sample sizes are necessary to validate our results.
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Introduction
Prostate cancer is one of the most common cancers and the
second leading cause of cancer mortality in Caucasian men, but its
incidence varies considerably between human populations [1].
Based on a recent survey, an approximately 1.6-fold greater
incidence of prostate cancer was diagnosed and a 2.4-fold greater
mortality reported in African-American men compared to
European-American men [2]. In addition, Asian populations have
shown a general trend of rising incidence of the cancer after
adopting westernized lifestyles, although the incidence is still lower
in Asia than Western countries [3,4]. It appears that multiple
variables including ethnic origins, environmental, and genetic
factors are likely linked to prostate cancer [5–8].
Mitochondria have been implicated in malignancy and cancer
biology, explained by their essential role in the generation of ATP
and for regulating apoptosis [9,10]. Recent studies suggest that
mitochondrial DNA (mtDNA) mutations may play an important
role in prostate carcinogenesis. For instance, a transmitochondrial
cybrid experiment demonstrated that the resulting mutant cybrids
appeared to generate tumors that were seven times larger than the
wild-type cybrids, whereas the wild-type cybrids barely grew in the
mice [7]. Jessie et al. [11] found that the average number of
mtDNA deletions in the malignant prostate of patients increased
with age. In addition, somatic mtDNA mutations that occur well
before changes in tissue histopathology indicative of prostate
cancer are highly informative about the oncogenesis of the disease
[12].
Since mtDNA is haploid and lacks recombination, specific
mutations in the mtDNA genome leading to human diseases arise
in particular genetic backgrounds referred to as haplogroups [13].
Human populations usually carry several mtDNA haplogroups
defined by unique sets of mtDNA polymorphisms, reflecting
mutations accumulated by a discrete maternal lineage [14,15],
but the sets and their frequencies differ between populations.
Thus, haplogroup association studies have been used to assess the
role of mtDNA variants in various complex diseases. Recently,
Booker et al. [8] noted that the inheritance of mtDNA
haplogroup U was associated with an approximately 2-fold
increased risk of prostate cancer and 2.5-fold increased risk of
renal cancer in North American individuals with European
ancestry. Such a finding needs to be investigated in an
independent population to determine whether a causal role of
mtDNA haplogroups in the cancer can also be detected
elsewhere, for example in the different maternal lineages in east
Asia.
To assess the possible contribution of mtDNA haplogroup-
specific mutations to the occurrence of prostate cancer, we have
therefore investigated the association between common mtDNA
lineages and a predisposition to the cancer in the Korean
population by examining 139 prostate cancer cases and 122
corresponding controls.
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Patients and controls
We analyzed a total of 139 Korean prostate cancer patients,
who were recruited for the study from the urology department of
the Eulji University School of Medicine in Seoul and Daejeon,
Korea. The DNA samples included subsets of the samples
examined by Kim et al. [16]. Histological classification of prostate
cancer was determined according to the World Health Organi-
zation (WHO) recommendations and the Gleason pattern
(Table 1). Prostate cancer tissue specimens from all of the patients
were collected from frozen samples. In addition, a total of 122
Korean men who had been diagnosed as free of prostate cancer by
the Eulji University hospital in Seoul and Daejeon, Korea were
recruited as normal controls. These subjects were selected at
random (and therefore likely to be unrelated) from the same
geographical area as the cases. This study was approved by the
Ethics Committee and institutional review boards of Eulji Medical
Center of the Eulji University School of Medicine in Seoul, and
separate written informed consent was obtained for screening and
for enrollment from all participants.
DNA extraction and genotyping
Genomic DNAs for patients and controls were extracted from
peripheral blood leukocytes using standard protocol [17]. Screening
for mtDNA haplogroups D, D4a, D4b, D4, G, M7, M7a, M7b, M8,
M8a, M, N, N9, Y, A, B, and F in Koreans (Table 2) was performed
using the multiplex amplified product length polymorphism (APLP)
method [18].EachPCR reaction wasperformed ina total volumeof
20 mlc o n t a i n i n g2 5n go fg e n o m i cD N A ,0 . 2m Md N T P s ,1 . 5m M
MgCl2,1 6PCR buffer (Applied Biosystems, Foster city, CA, USA),
1.0 U ampliTaq Gold
TM DNA polymerase (Applied Biosystems,
Foster City, CA, USA) and appropriate concentration of primers.
Primers and concentrations were described in Umetsu et al. [18].
The PCR amplification was carried out using a GeneAmpH PCR
system 9700 thermal cycler (Applied Biosystems, Foster City, CA,
USA) under the conditions: 95uC for 15 min, 32 cycles of 94uCf o r 10 sec,52uCfor10 sec,72uC5 sec,and afinalextensionat72uCfo r
3 min. The band patterns of the alleles were evaluated on 10%
native PAGE gels and visualized by silver staining. Haplogroups D5,
G2,C,B5and F1(Table2)weredeterminedbyPCR-RFLPmethod
[19]. The resulting restriction fragments were resolved by electro-
phoresis in 1.5% QA-Agarose
TM agarose (Q-BioGene, OH, USA)
gels, visualized by ethidium bromide staining. The nomenclature of
the mtDNA haplogroups followed previous reports [20,21]. All
samples were classified on the basis of the criteria shown in Table 2.
Data analyses
Mitochondrial DNA haplogroup frequencies were calculated by
counting from the observed phenotypes. To test for significant
population differentiation between all pairs of samples for the
prostate cases and the control groups, we used an Exact Test
implemented in the Arlequin package version 2.0 [22]. The
significance level of the test was applied with a probability of
,0.05 as cutoff point. In addition, a test of proportion and odds
ratios (OR) with 95% confidence intervals (CI), and a Fisher’s
Exact Test on a 262 table were calculated using the statistical
software program (http://www.quantitativeskills.com/sisa/).
Results and Discussion
We analyzed 22 mtDNA haplogroups using APLP and PCR-
RFLP methods in the cancer and control samples, most of which
are the common set of haplogroups in east Asia. The haplogroup-
Table 1. Clinicopathological characteristics of Korean
prostate cancer patients and control groups surveyed here.
Characteristic Category
Prostate Cancer
Patient (n=139) Control (n=122)
Age (year) #55 5 (3.60%) 39 (31.97%)
56–60 11 (7.91%) 20 (16.39%)
61–65 25 (17.99%) 33 (27.05%)
.65 98 (70.50%) 30 (24.59%)
[70.668.3]
* [59.6610.8]
*
PSA (mg/ml) #4.0 15 (10.79%) 113 (92.62%)
4.1–10.0 41 (29.50%) 3 (2.46%)
10.1–20.0 24 (17.27%) 3 (2.46%)
.20.0 59 (42.45%) -
Not available - 3 (2.46%)
Gleason score 2–6 47 (33.81%) -
7 35 (25.18%) -
8–10 56 (40.29%) -
Not available 1 (0.72%) -
*Mean age6SD.
doi:10.1371/journal.pone.0002211.t001
Table 2. Polymorphic multiplex APLP and restriction variants
determining mtDNA haplogroups in this study.
Haplogroup Key multiplex APLP and restriction
* variants
M
* 10400T
D
* 5178A 10400T
D4 3010A 5178A 10400T
D4a 3010A 5178A 10400T 14979C
D4b 3010A 5178A 8020A 10400T
D5 5178A -10394DdeI/-10397AluI 10400T
G
* 4833G 10400T
G2 4833G -7598HhaI 10400T
M7
* 6455T 10400T
M7a 4386C 6455T 10400T
M7b 6455T 10400T 12811C
M8
* 10400T 15487T
M8a 8684T 10400T 15487T
C 10400T -13259HincII/+13262AluI 15487T
N
* 10398A/10873T
N9
* 5417A 10398A/10873T
Y 5417A 10398A/10873T 14178C
A 1736G 10398A/10873T
B
* 9-bp deletion 10398A/10873T
B5 9-bp deletion +10394DdeI 10398A/10873T
F
* 3970T 10398A/10873T
F1 3970T 10398A/10873T -12406HpaI/HincII
*Sites are numbered from the first nucleotide of the recognition sequence. A
plus sign (+) indicates the presence of a restriction site, and a minus sign (2)
indicates the absence of restriction site.
doi:10.1371/journal.pone.0002211.t002
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quality, thus minimizing noise that would hinder the interpretation
of the variation in our samples [23]. Frequency distributions of the
prevalence of mtDNA haplogroups and subhaplogroups in
Koreans are listed in Figure 1. The Korean population surveyed
here is characterized by a high frequency of haplogroup D4
lineages (and its sublineages) in both groups of prostate cancer
patients (28.8%) and normal controls (27.9%) (Figure 1). In total,
thus, mtDNA haplogroups D and their subhaplogroups (D4a,
D4b, D4, and D5) were found to be the most prevalent maternal
lineages in both samples of prostate cancer patients (36.0%) and
normal controls (36.9%), and are widespread in northeast Asia. In
addition, southeast Asian-prevalent mtDNA lineages of (sub)ha-
plogroups B, M7, and F are also found at moderate frequencies in
the population. This result is consistent with previous mtDNA and
Y-chromosomal DNA surveys, showing that the Koreans possess
lineages from both the southern and northern haplogroup
complexes of east Asia [20,24].
Haplogroup U, reported by Booker et al. [8] to be over-
represented in prostate cancer patients in North American
individuals, was absent from our sample, which made it impossible
to assess the correlation between this lineage and cancer cases.
Based on our result, there were no statistically significant
differences in the distribution of mtDNA haplogroup frequencies
between all pairs of samples for the case and control groups
(Figure 1). In addition, each haplogroup was first tested separately
and then phylogenetically-combined haplogroups were tested
using OR and their 95% CI, and a Fisher’s exact test (Table 3).
We found no association between the cancer and the control
groups for each haplogroup. When comparing the distribution of
phylogenetically-combined haplogroups in patients to that in the
control group, there were again no significant differences between
cancer groups and the control distribution for haplogroups D, G,
M7, M8, N9, B, and F (Table 3). Thus, our data imply that specific
mtDNA mutations/lineages did not appear to have a significant
effect on a predisposition to prostate cancer in the Korean
population. However, the sample size of this survey may not
provide adequate power to detect associations with the large
number of haplogroups present in the sample (Figure 1). Thus,
further studies with larger sample sizes are necessary to validate
our results, because even association with fairly common
haplogroups and large effects may be missed with the limited
sample sizes.
Recently, Kim et al. [16] also found no association between Y
chromosome haplogroups and the relative risk of prostate cancer,
which contrasts with previous findings in the Japanese-American
population [25]. Nuclear gene mutations have also been linked to
mitochondrial diseases because most proteins involved in mtDNA
maintenance are nuclear-encoded [15]. Thus, further works on
nuclear gene disorders that contribute to the onset of the
mitochondrial diseases need to be investigated for better
understanding of the pathogenesis of the disease.
Age and family history are important risk factors for prostate
cancer, together with geographical origin [26]. We cannot rule
out the possibility of the effect of age difference between the
case and control samples, since it is not clear whether some
controls may subsequently go on to develop prostate cancer. In
fact, it should be noted that the mean age of controls
(59.6610.8) is less than that of cancer patients (70.668.3)
(Table 1). Nevertheless, this effect seems likely to be small.
Recent surveys from Asia (e.g., Japan, Singapore and Korea)
have shown a general trend of a rising incidence of prostate
cancer [3]. The changing demography of prostate cancer in
Asia may better be explained by environmental factors. This
possibility is supported by the observation that many Asian
countries may be losing their protective dietary habits and
acquiring high-risk ones by adopting westernized lifestyles
[4,16]. It leads us to conclude that multiple variables including
ethnic background, environmental, and genetic factors are likely
linked to prostate cancer.
Figure 1. Mitochondrial DNA haplogroup distribution in prostate cancer cases and controls in the Korean population. The
parsimonious tree on the top shows the evolutionary relationship of 22 haplogroups; capital letter-number codes denote haplogroups, all mutations
are indicated by the substituted nucleotides after the number.
aProstate cancer;
bNormal control; Exact test P value (s.e.)=0.60646(0.0374).
doi:10.1371/journal.pone.0002211.g001
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additional genetic markers and larger diverse samples could help
to evaluate the joint actions of genetic background and
environmental factors for the fuller understanding of the etiology
of prostate cancer.
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